Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
INOVIO (NASDAQ: INO) announced that an abstract for INO-3107, targeting Recurrent Respiratory Papillomatosis (RRP), has been accepted for oral presentation at the ABEA program during the COSM 2023 in Boston, scheduled for May 5, 2023. The presentation will showcase safety and immunogenicity data from both cohorts of a recently completed Phase 1/2 trial involving 32 RRP patients. RRP, primarily caused by HPV-6 and HPV-11, leads to the growth of benign warts in the respiratory tract but can cause serious complications. INO-3107 is a clinical-stage DNA medicine aimed at inducing T cell responses against these HPV types, potentially curbing papilloma growth. In July 2020, INO-3107 received Orphan Drug Designation from the FDA.
INOVIO (NASDAQ: INO) announced a positive opinion from the European Committee for Orphan Medicinal Products (COMP) regarding its application for orphan drug designation for INO-3107, intended for treating Recurrent Respiratory Papillomatosis (RRP). This rare disease, often caused by HPV types 6 and 11, leads to small growths in the respiratory tract, posing severe risks like airway obstruction. The European Commission is expected to make a final decision by late May 2023. Orphan designation is crucial for medicines targeting rare, life-threatening diseases affecting fewer than 5 in 10,000 individuals in the EU.